Literature DB >> 19593408

The immunohistochemical expression of growth hormone-releasing hormone receptor splice variant 1 is a favorable prognostic marker in colorectal cancer.

Elena Theophanous1, Constantina Petraki, Andreas Scorilas, Vassilios Komborozos, George Veloudis, Jozsef L Varga, Marta Zarandi, Andrew V Schally, Michael Koutsilieris.   

Abstract

Hypothalamic growth hormone (GH)-releasing hormone (GHRH) regulates the release of GH from the pituitary gland. The receptors for GHRH (GHRH-R) are expressed predominantly in the pituitary. Recent evidence demonstrates that splice variants of the GHRH receptor are also expressed in several nonpituitary tissues, both normal and tumoral, as well as in cancer cell lines. The aim of this study was to investigate the expression of the splice variant 1 (SV-1) of GHRH-R in colorectal cancer (CRC). Seventy patients who underwent partial colectomy for CRC were enrolled in the study. Immunohistochemical expression of SV-1 was studied in paraffin-embedded sections of patient tumor tissue. A cytoplasmic supranuclear expression of SV-1 was observed in CRC as well as in the normal colon mucosa. Tumor grade and pathological stage were negatively correlated with expression of SV-1 (P = 0.012 and P = 0.013, respectively). CRCs metastatic to the liver showed a lower expression of SV-1 than did primary tumors, but this difference was not statistically significant. Kaplan-Meier and Cox univariate survival analyses indicated an improved survival time in patients with high SV-1 compared with those with low GHRH-R expression, but this difference was not statistically significant. The immunohistochemical expression of SV-1 seems to be a favorable prognostic factor in CRC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19593408      PMCID: PMC2707517          DOI: 10.2119/molmed.2008.00132

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  32 in total

Review 1.  Pathophysiology of uterine leiomyomas.

Authors:  M Koutsilieris
Journal:  Biochem Cell Biol       Date:  1992-05       Impact factor: 3.626

2.  Development of a polyclonal antiserum for the detection of the isoforms of the receptors for human growth hormone-releasing hormone on tumors.

Authors:  Gabor L Toller; Judit E Horvath; Andrew V Schally; Gabor Halmos; Jozsef L Varga; Kate Groot; David Chism; Marta Zarandi
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-06       Impact factor: 11.205

3.  Mitogenic effects of insulin and insulin-like growth factors on PA-III rat prostate adenocarcinoma cells: characterization of the receptors involved.

Authors:  C Polychronakos; U Janthly; J G Lehoux; M Koutsilieris
Journal:  Prostate       Date:  1991       Impact factor: 4.104

4.  Stromal fibroblasts are required for PC-3 human prostate cancer cells to produce capillary-like formation of endothelial cells in a three-dimensional co-culture system.

Authors:  R Janvier; A Sourla; M Koutsilieris; C J Doillon
Journal:  Anticancer Res       Date:  1997 May-Jun       Impact factor: 2.480

5.  Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro.

Authors:  V J Csernus; A V Schally; H Kiaris; P Armatis
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

6.  Urokinase-type plasminogen activator: a paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases.

Authors:  M Koutsilieris; G Frenette; C Lazure; J G Lehoux; M V Govindan; C Polychronakos
Journal:  Anticancer Res       Date:  1993 Mar-Apr       Impact factor: 2.480

Review 7.  New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs.

Authors:  A V Schally; K Szepeshazi; A Nagy; A M Comaru-Schally; G Halmos
Journal:  Cell Mol Life Sci       Date:  2004-05       Impact factor: 9.261

8.  Mitogen(s) for endometrial-like cells can be detected in human peritoneal fluid.

Authors:  M Koutsilieris; L Allaire-Michaud; M Fortier; A Lemay
Journal:  Fertil Steril       Date:  1991-11       Impact factor: 7.329

9.  Increased activity of antagonists of growth hormone-releasing hormone substituted at positions 8, 9, and 10.

Authors:  Jozsef L Varga; Andrew V Schally; Judit E Horvath; Magdolna Kovacs; Gabor Halmos; Kate Groot; Gabor L Toller; Zoltan Rekasi; Marta Zarandi
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-30       Impact factor: 11.205

10.  Three-dimensional type I collagen gel system for the study of osteoblastic metastases produced by metastatic prostate cancer.

Authors:  M Koutsilieris; A Sourla; G Pelletier; C J Doillon
Journal:  J Bone Miner Res       Date:  1994-11       Impact factor: 6.741

View more
  2 in total

1.  Growth hormone-releasing hormone receptor splice variant 1 is frequently expressed in oral squamous cell carcinomas.

Authors:  Nikolina Dioufa; Elena Farmaki; Andrew V Schally; Hippokratis Kiaris; Dimitris Vlahodimitropoulos; Athanasios G Papavassiliou; Christos Kittas; Norman L Block; Ioulia Chatzistamou
Journal:  Horm Cancer       Date:  2012-03-23       Impact factor: 3.869

2.  Ferulic Acid Exerts Anti-Angiogenic and Anti-Tumor Activity by Targeting Fibroblast Growth Factor Receptor 1-Mediated Angiogenesis.

Authors:  Guang-Wei Yang; Jin-Song Jiang; Wei-Qin Lu
Journal:  Int J Mol Sci       Date:  2015-10-12       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.